Regeneron Pharmaceuticals (NASDAQ:REGN) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.53 by 19 Brokerage Firm. 6 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 10 Brokerage Firms have advised hold. 2 Analysts have rated it as strong sell.
Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Wells Fargo downgrades its outlook on Regeneron Pharmaceuticals (NASDAQ:REGN). The current rating of the shares is Market Perform, according to the research report released by the firm. Previously, the company had a rating of Outperform. The rating by the firm was issued on April 20, 2016.
Regeneron Pharmaceuticals (NASDAQ:REGN): The stock price is expected to reach $ 489.94 in the short term. The number of analysts agreeing with this consensus is 18. The higher estimate for the short term price target is at $668 while the lower estimate is at $325. The standard deviation of the price stands at $82.74.
Regeneron Pharmaceuticals (NASDAQ:REGN) witnessed a decline in the market cap on Tuesday as its shares dropped 2.13% or 7.52 points. After the session commenced at $354, the stock reached the higher end at $354 while it hit a low of $342.78. With the volume soaring to 1,183,509 shares, the last trade was called at $345.14. The company has a 52-week high of $605.9299. The company has a market cap of $36,267 million and there are 105,078,593 shares in outstanding. The 52-week low of the share price is $342.75.
Regeneron Pharmaceuticals, Inc. has lost 5.83% in the last five trading days and dropped 10.59% in the last 4 weeks. Regeneron Pharmaceuticals, Inc. has dropped 8.77% during the last 3-month period . Year-to-Date the stock performance stands at -36.42%.
Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.